Natasja Brooijmans
5PUBLICATIONS
58CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jun 04, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models.Raymond A Pagliarini, Jack A Henderson, Benjamin C Milgram
|May 29, 2024
An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.Alison J Davis, Natasja Brooijmans, Jason D Brubaker
|Sep 15, 2023
Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science.Darrin D Stuart, Angel Guzman-Perez, Natasja Brooijmans
|Aug 25, 2023
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts.Leonard Buckbinder, David J St Jean, Trang Tieu
|Nov 03, 2017
A precision therapy against cancers driven by KIT/PDGFRA mutations.Erica K Evans, Alexandra K Gardino, Joseph L Kim
Pageof 1
Frequent Collaborators
3 joint publications
Erica L Jackson
3 joint publications
Angel Guzman-Perez
3 joint publications
Gregory V Kryukov
3 joint publications
Darrin D Stuart
2 joint publications
Alison J Davis
2 joint publications
Xing Julia Zhu
2 joint publications
Weixue Wang
2 joint publications
Timothy P LaBranche
2 joint publications
Michael R Huff
2 joint publications
Brendan J Hilbert
